T1D vaccine

Vactech is developing a vaccine for the prevention of Type 1 Diabetes (T1D). This multivalent vaccine is based on a patented composition which makes it effective against those enterovirus types (Coxsackie B serotypes) that link to this disease. In addition, the vaccine is designed to prevent several other enterovirus diseases and possibly also Celiac Disease. Preclinical proof-of-concept studies have confirmed the efficacy and safety of the vaccine and prediction models suggest that it could prevent at least 50% of Type 1 Diabetes cases.

Vaccine strengths

  • Simple product
  • Large target population, *)
  • Strong scientific evidence
  • Patented vaccine composition
  • Proof-of-concept in mouse trials
  • Favorable safety and immunogenicity outcomes in Phase 1 human trial
  • First to the market
  • Product family of vaccines, antivirals and diagnostics

*) Prevention of T1D: The general population or those carrying genetic predisposition to T1D and comprising about 20% of the general Caucasian population. Prevention of acute Coxsackie B virus diseases (e.g. myocarditis, meningitis): The general population and vulnerable population. Prevention of Celiac Disease: The general population or genetic risk groups.

Vactech's diabetes vaccine (PRV-101) is codeveloped with our strategic partner, Provention Bio Inc. It is based on the similar conventional effective and safe technology, which is used in other inactivated enterovirus vaccines such as polio and EV71 vaccines. The PRV-101 vaccine recently passed the First-in-Human Phase 1 trial showing good tolerability and immunogenicity. See, ClinicalTrials.gov Identifier: NCT04690426.